Medical Supplies and Services News

Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT...

Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For...

2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative...

2024/25 Delårsrapport, 9M 2024/25 1. oktober 2024 - 30. juni 2025 Coloplast leverede en organisk vækst på 7% og en overskudsgrad1 på 28% i 3. kvartal. Den rapporterede omsætning i danske kroner...

Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new...

Coloplast ændrer i ledelsesteamet  Coloplasts bestyrelse laver ændringer til ledelsesteamet (ELT) for at understøtte en succesfuld eksekvering af ny strategi. I løbet af de seneste måneder har...

Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following statement in response to recent unusual trading...

苏黎世, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI 在其 2025 年格拉斯哥大会期间启动了抗生素过敏意识宣传活动。 这一倡议开启了一项全球行动，旨在解决误标问题及其与抗菌素耐药性 (AMR) 的关联。 全球行动号召 抗生素过敏误标影响全球数百万人。 不准确的标注导致人们回避一线治疗，并过度使用二线抗生素，从而加剧了 AMR。...

蘇黎世, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI 於格拉斯哥舉行的 2025 年度大會上啟動了抗生素過敏意識宣傳活動。 此倡議開創了一項全球行動，以解決錯誤標籤問題及其與抗微生物劑耐藥性 (AMR) 的關聯。 全球行動呼籲 抗生素過敏錯誤標籤影響全球數百萬人。...

ZURICH, 15 août 2025 (GLOBE NEWSWIRE) -- L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025...